In this weeks oncology round-up, we’ve gathered information on the role of long non-coding RNAs in the development of pancreatic cancer, insight into a gene signature in localized prostate cancer, and new applications of cells in cancer therapies.
In addition to the huge news of an FDA approval of the first treatment for COVID-19 (Gilead Science’s antiviral IV drug remdesivir), we’re looking at the FDA approval of the first treatment for Ebola, as well as a novel microneedle-based skin patch.
What’s new in oncology for October 2020? We’ve rounded up information on potential cancer-reducing drugs, liquid biopsy to detect brain tumors, and new immune-like characteristics of cells.
In addition to continued progress and information regarding the ongoing COVID-19 pandemic, October brings forth information on predicting this seasons influenza strain, the body’s response to viral infection, and a potential rotavirus cure.
This February 29th, PharPoint acknowledges Rare Disease Day. We are relentless in supporting clients so that they may advance rare disease research and the approval of breakthrough treatments.
Information regarding the novel coronavirus is rapidly evolving as scientists and public-health officials race to uncover important details on the spread and treatment of the virus. Explore PharPoint’s news roundup and learn more about our extensive infectious disease experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.